Osteopontin increases breast cancer cell sensitivity to specific signaling pathway inhibitors in preclinical models.
AuthorsMutrie JC, Chambers AF, Tuck AB
JournalCancer Biol Ther
PubMed ID21795853
Src kinase and Hsp90 play important roles in malignancy-promoting signaling pathways in a variety of cancers and related targeting agents are presently in clinical trials. To help improve the success of Src kinase and Hsp90 inhibitor therapies, identifying sensitive patient populations will be essential. Osteopontin (OPN), a secreted integrin-binding glycophosphoprotein, ... More